Skip to main content
. 2023 Sep 18;19(15):4948–4966. doi: 10.7150/ijbs.86632

Figure 9.

Figure 9

Improved anti-tumor and immunomodulation effects of CD19-s47-CAR T cells in humanized mouse models. (A) Schematic representation of the experimental plan used to evaluate anti-NHL activity and immunomodulation effect in vivo using PBMCs-PDX mice derived from primary NHL cells. (B) Primary NHL cells (P4) were implanted subcutaneously into B-NDG mice, and the tumor volume was recorded. (C) 30 days after subcutaneous inoculation of NHL cells, mice were sacrificed, tumor tissues were removed, then tumors were photographed. (D) Tumor tissues in C were weighed. (E) Flow cytometry analyses showing human CD3+ cells in spleen and BM at the experimental endpoint of each mouse (n = 3). (F) Frequency of M2-like (CD206+) TAMs in monocytes (CD14+) in spleen, BM and tumor from mice (n = 3). Data in B, D, and E-F are presented as mean ± SD and analyzed by One-way ANOVA with Turkey's multiple comparison test.